Gilead Sciences Inc. (GILD – Analyst Report) just released their fourth quarter fiscal 2015 earnings results, posting earnings of $3.32 and revenue of $8.5 billion.

Currently, GILD has a Zacks Rank #1 (Strong Buy), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.


1. Beat earnings estimates. The company posted an EPS of $3.32, beating our Zacks Consensus Estimate of $2.91.

2. Beat revenue estimates. The company saw revenue figures of $8.5 billion, surpassing our estimate of $8.114 billion.

3. Total product sales for the fourth quarter of 2015 were $8.4 billion compared to $7.2 billion for the fourth quarter of 2014. Total product sales during 2015 were $32.2 billion compared to $24.5 billion in 2014.

4. “Antiviral product sales, which include products in our HIV and liver diseases areas, were $7.9 billion for the fourth quarter of 2015 compared to $6.7 billion for the fourth quarter of 2014 primarily as a result of the launch of our HCV products in Japan and continued launches of our HCV products across Europe,” the company said in its press release.

5. GILD was down $0.22, or 0.26%, to $82.50 as of 4:28 PM ET in after hours trading shortly after its earnings report was released.

Here’s a graph that looks at Gilead’s latest surprise acitivty (note: the displayed estimate EPS is the Most Accurate Estimate, not the Zacks Consensus Estimate):

Gilead Sciences Inc. (GILD – Analyst Report) Street Actual & Estimate EPS – Last 5 Quarters | FindTheCompany

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective. Gilead was founded in 1987 and is headquartered in Foster City, California.

Print Friendly, PDF & Email